EN DE
Watch ToolGen Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ToolGen Inc. (199800) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of ToolGen Inc. stock KRW 17,356, price KRW 30,700, that is 43.5% below the price, quality 35 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

TI ToolGen Inc. logo Thin data Nov 10, 2026

ToolGen Inc.

199800 · KQ
Very expensive, weak quality

Our calculation puts a fair price 43% below what the stock costs today.

Expensive Growth (revenue 5y +12.9 %/yr in KRW)
Moderate debt
Fair value 17,356 KRW · Strongly overvalued
Quality 35/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch ToolGen Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

138,200 KRW 26,700 KRW Fair Value 17,356 KRW Dec 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

59‑month range 26,700 KRW – 138,200 KRW · fair‑value band 13,017 KRW – 21,694 KRW · the 30,700 KRW price screens above the 17,356 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow ToolGen in your weekly email

Every Wednesday you see whether ToolGen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ToolGen Incorporated, a biotechnology company, focuses on the development of genome editing technology in South Korea. The company develops clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene scissors for gene editing in eukaryotic cells.

Show moreShow less

It is involved in patent monetization, treatment, and seed businesses. ToolGen Incorporated was founded in 1999 and is based in Seoul, South Korea.

Stock analysis

ToolGen Inc. (199800) currently trades at 30,700 KRW, while our estimate is 17,356 KRW, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 13,017 KRW (bear) to 21,694 KRW (bull), the price of 30,700 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

ToolGen Inc. reported revenue of 1.3B KRW in FY2025 versus 1.6B KRW in FY2021, a compound −4.9%/yr. Reported net income was −36.8B KRW in FY2025.

Key figures

Market cap 275B KRW (≈ $206M) Micro · EPS (TTM) −4,004 KRW · Return on equity −77.4% · Return on assets (EBIT) −26.9% (5-year average) · Operating margin −1,415% · Revenue (TTM) 1.8B KRW · Revenue growth (YoY) +163% · Free cash flow −20.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 78% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, 199800 screens richer than that median.

Fair Value

Bear 13,017 KRW Fair Value 17,356 KRW Bull 21,694 KRW
Price 30,700 KRW · Downside -43.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 24
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 34
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+46.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,098.7% (2020) → −1,782.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

199800 screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ToolGen Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −43.5% · Bottom 25%
Profitability
Return on assets −59.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 163.1% · Top 25%
Balance sheet
Debt / equity 1.08× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.93× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)46 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 199800
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 199800
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 199800
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 199800
argenx SE ARGX $971.55 $908.40 −7% vs 199800
CSL Limited CSL A$201.68 A$181.40 −10% vs 199800
Moderna, Inc MRNA $250.83 $158.70 −37% vs 199800
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 199800
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 199800
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 199800

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ToolGen Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ToolGen Inc. Fair Value". https://www.fairvalue-calculator.com/stock/199800

Frequently asked questions

Is ToolGen Inc. (199800) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 17,356 KRW versus a price of 30,700 KRW, about 43% lower (overvalued).
What is the fair value of 199800?
Our estimate for ToolGen Inc. is 17,356 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 30,700 KRW.
What is the quality score of 199800?
ToolGen Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ToolGen Inc. (199800)?
Our calculated price target is the estimate of 17,356 KRW (as of Nov 10, 2026). Cautious scenario 13,017 KRW, optimistic scenario 21,694 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ToolGen Inc. stock forecast for 2026?
Our estimate puts fair value at 17,356 KRW, about 43% lower versus a price of 30,700 KRW (overvalued). Cautious scenario 13,017 KRW, optimistic scenario 21,694 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ToolGen Inc. (199800)?
ToolGen Inc. reported trailing-twelve-month revenue of about 1.8B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of ToolGen Inc. (199800)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ToolGen Inc. it is 17,356 KRW per share (as of Nov 10, 2026), against a price of 30,700 KRW.
Is ToolGen Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 199800 trades above its calculated fair value: price 30,700 KRW, fair value 17,356 KRW, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 199800?
No. The price is what the market pays today (30,700 KRW); the fair value is what the company's own numbers justify (17,356 KRW). For ToolGen Inc. the two are 13,344 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ToolGen Inc. worth?
The market values ToolGen Inc. at about 275B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 30,700 KRW; our models calculate a fair value of 17,356 KRW per share.
What do the bullish and bearish scenarios say about 199800?
Our models span a range for ToolGen Inc.: cautious scenario 13,017 KRW, base 17,356 KRW, optimistic 21,694 KRW per share (as of Nov 10, 2026, price 30,700 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ToolGen Inc. (199800)?
Balance-sheet figures for ToolGen Inc. (as of Nov 10, 2026): return on equity −77.4%, debt of 1.08 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 199800 from its 52-week high?
ToolGen Inc. trades at 30,700 KRW, about 78% below its 52-week high of 138,200 KRW and 10% above the low of 27,850 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 17,356 KRW is for.
Which stocks are comparable to ToolGen Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ToolGen Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price 30,700 KRW, calculated fair value 17,356 KRW (−43%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. ToolGen Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ToolGen Inc. (199800)?
The closing price on Nov 10, 2026 was 30,700 KRW. Our estimate is 17,356 KRW, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ToolGen Inc. right now?
The price sits above even our optimistic bull case (21,694 KRW). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ToolGen Inc.

How large is the market capitalisation of ToolGen Inc. (199800)?
The market capitalisation of ToolGen Inc. is 275B KRW (≈ $206M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ToolGen Inc. (199800)?
Earnings per share at ToolGen Inc. are −4,004 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ToolGen Inc. (199800)?
The return on equity (ROE) of ToolGen Inc. is −77.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ToolGen Inc. (199800)?
On an EBIT basis the return on assets of ToolGen Inc. is −26.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ToolGen Inc. (199800)?
The operating margin of ToolGen Inc. is −1,415% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ToolGen Inc. (199800)?
Revenue at ToolGen Inc. is growing +163% versus a year earlier (3y avg +20.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ToolGen Inc. (199800) generate?
The free cash flow of ToolGen Inc. is −20.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ToolGen Inc. (199800) carry?
The net debt of ToolGen Inc. is 25.8B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ToolGen Inc. in the live analysis

One click puts ToolGen Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.